If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 14
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Objective
Study of tandem, bispecific anti-CD19 anti-CD20 CAR-T cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Protocol No
IIT-SHAH-IL7-IL15-CD20-19
Categories
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B
Objective
Phase II MB-CART2019.1 for R/R DLBCL
Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Categories
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
Objective
Venetoclax and HMA Treatment of Older and Unfit Adults with FLT3 Mutated Acute Myeloid Leukemia (AML)
Protocol No
ECOG-MM1OA-EA02
Categories
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Mulitple Myeloma (CaMMouflage Trial)
Objective
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With RR MM
Protocol No
CARIBOU-CAMMOUFLAGE-CB-011A-MM
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-Directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Len
Objective
A Phase 3 Study of BMS-986393 in Adult Patients with RR or RRMM
Protocol No
BMS-CA0881007
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
Objective
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Protocol No
ALLIANCE-A041501-ALL
Categories
Phase I Study of LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-Cell Malignancies
Objective
Phase I Study of LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Protocol No
IIT-SHAH-PIRTO
Categories
A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma
Objective
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in subjects with r/r MM
Protocol No
GRACELL-GC012F-CD19-BCMA-001
A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Objective
A Phase 1 Study of ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies
Protocol No
INNOCARE-ICP-CL-01205
A Phase 2 Clinical Trial of Teclistamab and Daratumamab in Previously Untreated AL Amyloidosis (IMPACT-AL)
Objective
Teclistamab-Daratumamab in AL Amyloidosis
Protocol No
COLUMBIA-AAAV8827
Categories